Page 35 - 2019秋季手冊內頁-ebook測試

Utilization of Donor-derived LCL-EBVST post-HCT for EBV-LPD
• For prophylaxis: 0 of 110 develop EBV-LPD
• For treatment of EBV-LPD: 11 of 13 sustained CR
• Minimal toxicities
• Persistence of functional CTLs up to 9 years
• EBVST poor efficacy in lymphomas outside transplant setting
(2) Ad-LMP1/2/LCL-activated T-cells (Ad-LCL-EBVST) Utilization of Ad-LCL-EBVST for HL and NHL
• Highly effective as adjuvant post BMT or post chemotherapy alone
• Also effective in relapsed/refractory settings Problems of LCL-EBVST
• Long manufacturing time
• Complex procedures: live EBV, adenovirus vector
(3) Pepmixes stimulated EBVST (pep-EBVST) Characteristics of pep-EBVST
• Can target multiple viruses
• HLA-independent
• Effective and safe in HSCT settings
• Effective both as adjuvant and as salvage preliminary
• Improvement of technologies on the way
Preliminary Results of Allogeneic pep-EBVST Banks
• Partially HLA-matched required
• Effective and safe in HSCT settings
• Effective and safe outside HSCT settings
Prospects of VST Developments
• specificity and activity
• epitope spreading
• persistence
36